Navigation Links
New Treatment Mooted For Blood Pressure

InterCure, Ltd. has announced that it will be publishing a peer-reviewed clinical overview to test how efficient device-guided breathing is. RESPeRATE, a over-the-counter// therapeutic device that is approved by FDA could be a viable option to treat hypertension, the study says.

The article, published in the General Medicine Journal (http://www.medscape.com/viewarticle/539099) of Medscape (NASDAQ:WBMD), is authored by William J. Elliott, MD, PhD, professor of Preventive Medicine, Internal Medicine and Pharmacology at Rush Medical College, Ill., and Joseph L. Izzo, Jr., MD, professor of medicine and vice chair of Medical Research at the University of Buffalo, N.Y.

The article confirms the body of evidence from seven published clinical studies concluding that routine use of RESPeRATE, either alone or as an adjunctive treatment with lifestyle modifications or prescription drugs, significantly lowered blood pressure with no adverse side effects. The study also reviews the physiological mechanism of action of device-guided breathing.

A summary of the results of the seven studies shows an average all-day reduction of 14/8 mm Hg within four to six weeks of commencement of 15-minute-daily treatments with RESPeRATE. The reduction in blood pressure was consistent between studies, whether measurements were taken in the home, 24-hour ambulatory setting or physician's office. Larger blood pressure reductions were seen in older individuals and those with higher baseline readings, regardless of whether they were also being treated with prescription antihypertensive medications.

The authors summarize the patient populations for whom device-guided breathing appears to be beneficial: (1) prehypertensives and white-coat or labile hypertensives who might benefit from reducing stress and sympathetic activity; (2) patients with isolated systolic hypertension; and (3) patients with resistant hypertension (uncontrolled blood pressure despite use of a diuretic and at least two other medications at maximum approved doses).

"When I was first introduced to RESPeRATE, I was skeptical, but after seven trials, the body of data speaks for itself. I have seen first-hand that as long as patients use the device regularly, blood pressure is reduced, with no side effects," says Dr. William Elliott, Rush Medical Center. "Controlling hypertension requires a comprehensive approach, and device-guided breathing provides an additional effective therapeutic modality to offer our patients."

More than 65 million Americans have high blood pressure, and even with traditional treatment methods of diet, exercise and medication, 70 percent of that population is either unable to reach their lower blood pressure goals or can't tolerate the side effects of medications. Left untreated, high blood pressure may lead to heart attack, stroke and kidney or heart failure.

Source: Eurekalert
'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/22/2017)... PA (PRWEB) , ... September 22, 2017 , ... ... soon as possible, and they often saves lives. However, if one isn’t accessible ... to widen the availability of defibrillation, I came up with this idea," said ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... House buildings, and Richard Pedranti Architect (RPA), a full-service architecture firm ... strategic partner’s Solsken Line of Model Homes . Independently, Ecocor and RPA ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... Pennsylvania, is pleased to offer in-home and online newborn sleep consultations . ... has on the body,” says company owner Courtney Zentz, a pediatric sleep professional, ...
(Date:9/22/2017)... California (PRWEB) , ... September 22, 2017 , ... Happy ... at a time - carries it into the entertaining and delicious worlds of ... Matt Gersper (founder of Happy Living) convinced him to turn his play into a ...
(Date:9/22/2017)... ... September 22, 2017 , ... “Cursed with a Curse: ... tithe, and the freedom experienced when breaking free from this misconception. “Cursed with ... M. Harrison. , Published by Christian Faith Publishing, Lysa M. Harrison’s new book ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
(Date:9/7/2017)... , Sept. 7, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Healthcare Conference at the Grand Hyatt hotel in New ... 2017 at 11:40 a.m. Eastern Time. A ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
Breaking Medicine Technology: